Adlon Therapeutics announced the launch of Adhansia XR (methylphenidate HCl extended-release capsules) for the treatment of attention deficit hyperactivity disorder (ADHD) in patients aged 6 years and older.
Adhansia XR is supplied in 25mg, 35mg, 45mg, 55mg, 70mg, and 85mg extended-release capsules; each bottle contains 30 capsules. For patients who have difficulty swallowing, the contents of the capsule may be sprinkled onto a tablespoon of applesauce or yogurt; the dose of a single capsule should not be divided.
Adhansia XR contains methylphenidate, a Schedule II controlled substance. Each capsule consists of multilayered beads, composed of an immediate-release (IR) layer which contains approximately 20% of the dose, and a controlled-release layer which contains approximately 80% of the dose.
“For some patients living with ADHD, managing symptoms outside of standard work or school hours can be difficult. Adhansia XR is a new option that may help address the needs of certain patients who could benefit from a longer duration of efficacy,” said Alice Mao, MD, Memorial Park Psychiatry, Houston.
Regarding safety, Adhansia XR carries a Boxed Warning for abuse and dependence. The most common adverse events in adult patients included insomnia, dry mouth, and decreased appetite; in pediatric patients, decreased weight was an additional adverse reaction.
Adhansia XR should not be substituted for other methylphenidate products on a milligram-per-milligram basis because these products have different pharmacokinetic profiles and may have different methylphenidate base compositions.
For more information visit adlontherapeutics.com.
This article originally appeared on MPR